Home » Stocks » PACB

Pacific Biosciences of California, Inc. (PACB)

Stock Price: $30.35 USD -1.00 (-3.19%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $30.25 -0.10 (-0.33%) Jul 23, 7:38 PM
Market Cap 6.04B
Revenue (ttm) 92.29M
Net Income (ttm) -59.29M
Shares Out 199.01M
EPS (ttm) -0.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $30.35
Previous Close $31.35
Change ($) -1.00
Change (%) -3.19%
Day's Open 31.41
Day's Range 29.83 - 31.41
Day's Volume 1,582,624
52-Week Range 3.57 - 53.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PacBio's (PACB) latest acquisition is expected to deliver the most advanced blend of sequencing solutions to transform the genomics landscape.

2 days ago - Zacks Investment Research

Pacific Biosciences of California Inc (NASDAQ: PACB) has agreed to acquire Omniome, a San Diego-based company developing a short-read sequencing platform.  Under the terms of the agreement, PacBio will ...

5 days ago - Benzinga

Collaboration to develop production-scale HiFi Sequencing platform expected to Include technology from Omniome, Inc.

5 days ago - GlobeNewsWire

MENLO PARK, Calif. and SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-r...

5 days ago - GlobeNewsWire

MENLO PARK, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its second quarter 2021 financial results ...

5 days ago - GlobeNewsWire

You can get a lot of bang for the buck with these picks.

Other stocks mentioned: IONS, SKLZ
1 week ago - The Motley Fool

Cathie Wood's genomics ETF is making big bets on the "Genomic Age."

Other stocks mentioned: ARKG, EXAS, NTLA, NVTA
2 weeks ago - The Motley Fool

Pacific Biosciences' (PACB) latest research tie-up is likely to use HiFi Sequencing data on some of the most difficult cases of rare pediatric disease and provide insights into the treatment journey.

3 weeks ago - Zacks Investment Research

HiFi Sequencing will be used on a cohort of rare disease cases with the aim to identify numerous variants, both small and structural, that are not readily detectable by short-read sequencing HiFi Sequen...

1 month ago - GlobeNewsWire

MENLO PARK, Calif., June 11, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing platf...

1 month ago - GlobeNewsWire

Industry Veteran Will Lead PacBio's Commercial Footprint Across the Region Industry Veteran Will Lead PacBio's Commercial Footprint Across the Region

1 month ago - GlobeNewsWire

Twenty years after the human genome was sequenced, a new wave of discovery has begun.

1 month ago - The Motley Fool

A new breed of disruptors is delivering breakthroughs in genomics.

Other stocks mentioned: BEAM
1 month ago - The Motley Fool

Incredible scientific advances could reward investors -- if they have the patience.

Other stocks mentioned: TWST
1 month ago - The Motley Fool

Falling costs are ushering in a new era of screening for a dreaded disease.

Other stocks mentioned: EXAS, GH
2 months ago - The Motley Fool

MENLO PARK, Calif., May 04, 2021 (GLOBE NEWSWIRE) --  Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences:

2 months ago - GlobeNewsWire

Pacific Biosciences' (PACB) revenues grow in both its segments during the first quarter.

2 months ago - Zacks Investment Research

The company released its first-quarter earnings report, but that doesn't tell the whole story.

2 months ago - The Motley Fool

Shares of Pacific Biosciences (NASDAQ:PACB) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 4600.00% over the past year to ($0.45), which we...

2 months ago - Benzinga

MENLO PARK, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2021.

2 months ago - GlobeNewsWire

MENLO PARK, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, announced today that Dr...

2 months ago - GlobeNewsWire

Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

MENLO PARK, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its first quarter 2021 financial results ...

3 months ago - GlobeNewsWire

We're really excited that these genomics companies, says Ark's Simon Barnett

YouTube video

Simon Barnett, ARK Invest's genomics analyst, discusses the company's belief in Invitae, its other top picks and why ARK invests the way it does.

Other stocks mentioned: ADPT, ARKG, NVTA
3 months ago - CNBC Television

These two disruptive companies have long growth runways ahead of them.

Other stocks mentioned: NET
4 months ago - The Motley Fool

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?

4 months ago - Zacks Investment Research

MENLO PARK, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences:

4 months ago - GlobeNewsWire

The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.

Other stocks mentioned: PFE, MRNA
4 months ago - Investors Business Daily

The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.

Other stocks mentioned: AZN, BNTX, GILD, GSK, ILMN, JNJ, LLY ...
4 months ago - Investors Business Daily

Pacific Biosciences' (PACB) Sequel II HiFi sequencing gets utilized by LabCorp to detect SARS-COV-2 variants in the United States.

Other stocks mentioned: LH
5 months ago - Zacks Investment Research

The stock price of Pacific Biosciences of California a biotechnology company that develops gene sequencing systems, has seen a solid 27% rise over the last ten trading days, though it's down 4% over the...

5 months ago - Forbes

Labcorp Using PacBio's HiFi Sequencing to Detect SARS-CoV-2 Variants in the U.S. Labcorp Using PacBio's HiFi Sequencing to Detect SARS-CoV-2 Variants in the U.S.

5 months ago - GlobeNewsWire

Will SoftBank Group Corp.'s (SFTBY) huge investment in Pacific Biosciences of California Inc.(NASDAQ:PACB) turn out to be another home run for the Japanese conglomerate or will it be a swing and a miss ...

5 months ago - GuruFocus

Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.

5 months ago - Zacks Investment Research

ESSA Pharma Inc. (NASDAQ: EPIX) shares are trading higher after the company reported first-quarter earnings results and highlighted the presentation of Phase 1 pharmacology data of EPI-7386 for advanced...

Other stocks mentioned: ANAB, EPIX
5 months ago - Benzinga

With the trading day more than halfway over, the broad markets were trading sideways on Thursday.

Other stocks mentioned: CSCO, LYFT, UBER, VMW, CCJ, IRBT, MELI ...
5 months ago - 24/7 Wall Street

The pandemic didn't weigh on the genetic sequencing systems company nearly as much as earlier in 2020.

5 months ago - The Motley Fool

The gene sequencing company is receiving a $900 million investment from a renowned international conglomerate.

5 months ago - The Motley Fool

The gene sequencing company is receiving a $900 million investment from a renowned international conglomerate.

5 months ago - The Motley Fool

Pacific Biosciences (PACB) delivered earnings and revenue surprises of -102.33% and -0.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Pacific Biosciences (NASDAQ:PACB) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 0.00% over the past year to $0.37, which beat...

5 months ago - Benzinga

MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2020. Re...

5 months ago - GlobeNewsWire

Pacific Biosciences is getting an investment from a holding company.

5 months ago - The Motley Fool

MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”), a leading provider of high-quality, long-read sequencing platforms, today an...

5 months ago - GlobeNewsWire

SoftBank Group Corp (OTCMKTS: SFTBY) will reportedly invest $900 million into Pacific Biosciences of California Inc (NASDAQ: PACB), according to the Wall Street Journal, which comes on top of around 6% ...

Other stocks mentioned: SFTBY
5 months ago - Benzinga

Pacific Biosciences' (PACB) fourth-quarter results are likely to reflect strength in its Sequel system.

5 months ago - Zacks Investment Research

On Wednesday, February 10, Pacific Biosciences (NASDAQ:PACB) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

5 months ago - Benzinga

MENLO PARK, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of ge...

5 months ago - GlobeNewsWire

A new leadership team is betting that it can make long-read genome sequencing more competitive.

5 months ago - The Motley Fool

MENLO PARK, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of ge...

5 months ago - GlobeNewsWire

About PACB

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonuclease... [Read more...]

Industry
Diagnostics & Research
IPO Date
Oct 27, 2010
Stock Exchange
NASDAQ
Ticker Symbol
PACB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for PACB stock is "Buy." The 12-month stock price forecast is 47.25, which is an increase of 55.68% from the latest price.

Price Target
$47.25
(55.68% upside)
Analyst Consensus: Buy